Aims: The objective of the Coronary Calcification (CC) study was to determine in patients with chronic symptomatic coronary artery disease, if, in addition to standard therapy, nifedipine GITS, relative to placebo, would arrest or slow down the progression of calcium or the development of new atherosclerotic lesions in the coronary arteries. Methods and Results: The CC study was part of the ACTION trial. Multi-slice computerized tomography was used to measure and track the progression of CC. Five hundred and eighteen patients were included in this study. The changes in calcium score from baseline every 24 months, over a period of between 4.5 and 6 years, were similar in the nifedipine and placebotreatment groups (p = 0.8). Compared to placebo, more patients in the nifedipine group (71 vs. 60%) were free of new calcified atherosclerotic lesions during follow-up(p = 0.095). Conclusion: Nifedipine GITS was not effective in slowing down the progression of calcium in advanced atherosclerotic plaques in patients with stable angina pectoris. Although statistically not significant, Nifedipine demonstrated a trend in slowing down the development of new atherosclerotic lesions.

1.
Weinstein DB, Heider JG: Antiatherogenic properties of calcium antagonists. State of the art. Am J Med 1989;86:27–32.
2.
Henry PD: Calcium antagonists as anti-atherosclerotic agents. Arteriosclerosis 1990;10:963–965.
3.
Henry PD: Atherogenesis, calcium and calcium antagonists. Am J Cardiol 1990;66:3I–6I.
4.
Fleckenstein A, Frey M, Thimm F, Fleckenstein-Grun G: Excessive mural calcium overload–a predominant causal factor in the development of stenosing coronary plaques in humans. Cardiovasc Drugs Ther 1990;4(suppl 5):1005–1013.
5.
McCarthy JH, Palmer FJ: Incidence and significance of coronary artery calcification. Br Heart J 1974;36:499–506.
6.
Warburton RK, Tampas JP, Soule AB, Taylor HC, 3rd: Coronary artery calcification: Its relationship to coronary artery stenosis and myocardial infarction. Radiology 1968;91:109–115.
7.
Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD: Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol 2005;46:158–165.
8.
Lubsen J, Poole-Wilson PA, Pocock SJ, van Dalen FJ, Baumann J, Kirwan BA, Parker AB: Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Gastro-Intestinal Therapeutic System. Eur Heart J 1998;19(suppl I):I20–I32.
9.
Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE, Seabra-Gomes R, Soler-Soler J, Weber S: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004;364:849–857.
10.
Frison LJ, Pocock SJ: Linearly divergent treatment effects in clinical trials with repeated measures: efficient analysis using summary statistics. Stat Med 1997;16:2855–2872.
11.
Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289–1298.
12.
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633–638.
13.
Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI, et al: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528–2540.
14.
Henry PD, Bentley KI: Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest 1981;68:1366–1369.
15.
Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW: Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990;335:1109–1113.
16.
Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Nikutta P, Deckers JW: Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT (International Nifedipine Trial on Antiatherosclerotic Therapy) study. Cardiovasc Drugs Ther 1990;4(suppl 5):1047–1068.
17.
Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang YK, Hudon G, Lemarbre L, Reitman M, Joyal M, et al: A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990;82:1940–1953.
18.
Tulenko TN, Brown J, Laury-Kleintop L, Khan M, Walter MF, Mason RP: Atheroprotection with amlodipine: cells to lesions and the PREVENT trial. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial. J Cardiovasc Pharmacol 1999;33(suppl 2):S17–S22.
19.
Byington RP, Miller ME, Herrington D, Riley W, Pitt B, Furberg CD, Hunninghake DB, Mancini GB: Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). Am J Cardiol 1997;80:1087–1090.
20.
Koshiyama H, Tanaka S, Minamikawa J: Effect of calcium channel blocker amlodipine on the intimal-medial thickness of carotid arterial wall in type 2 diabetes. J Cardiovasc Pharmacol 1999;33:894–896.
21.
Motro M, Shemesh J: Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001;37:1410–1413.
22.
Simon A, Gariepy J, Moyse D, Levenson J: Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001;103:2949–2954.
23.
Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071–1080.
24.
Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS: Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation 1995;92:2157–2162.
25.
Shemesh J, Apter S, Itzchak Y, Motro M: Coronary calcification compared in patients with acute versus in those with chronic coronary events by using dual-sector spiral CT. Radiology 2003;226:483–488.
26.
Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389–2397.
27.
Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ: Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998;339:1972–1978.
28.
Budoff MJ, Lane KL, Bakhsheshi H, Mao S, Grassmann BO, Friedman BC, Brundage BH: Rates of progression of coronary calcium by electron beam tomography. Am J Cardiol 2000;86:8–11.
29.
Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Knez A, Menendez T, Maeffert R, Kusus M, Regenfus M, Bickel A, Haberl R, Steinbeck G, Moshage W, Daniel WG: Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 2002;106:1077–1082.
30.
Hecht HS, Harman SM: Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary preventionas determined by electronbeam tomography. Am J Cardiol 2003;91:42–45.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.